RxDoctor Payments Data

Daniel Vardeh, MD

Pain Medicine · East Sandwich, MANPI 1205132990

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $14,400 of the $19,713 with a category attached, or 73.0%. 7 manufacturers reported payments, led by Pfizer at 54.0% of the total. 2025 is the largest year on record at $18,565, more than ten times the $455 reported in 2019. Among pain medicine clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,713in general payments, 2019–2025

Across 72 payments — averaging $273.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$11K
  • AbbVie$8K
  • Lundbeck LLC$452
  • Abbott$267
  • SPR Therapeutics, Inc$116
  • Amgen$99
  • plus $76 from 1 others

What the payments were for

  • Consulting fees$1,8009%
  • Speaking & faculty fees$14,40073%
  • Travel & lodging$7184%
  • Food & beverage$2,79514%

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer6$10,639
AbbVie(2 entities)51$8,065
Lundbeck LLC9$452
Abbott2$267
SPR Therapeutics, Inc1$116
Amgen1$99
Lilly USA, LLC2$76

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,713 in reported general payments places this provider in the 90th percentile of 137 pain medicine providers in Massachusetts.

See all pain medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$180,335
Medicare patients
383
Services billed
9,470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe92$86,134
UbrelvyUbrogepant71$80,818
Nurtec OdtRimegepant Sulfate53$69,062
Emgality PenGalcanezumab-Gnlm61$42,312
Ajovy AutoinjectorFremanezumab-Vfrm26$28,362
QuliptaAtogepant15$24,404
BelbucaBuprenorphine Hcl11$6,749
Gabapentin168$4,076
Oxcarbazepine65$3,782
Amitriptyline Hcl142$3,145
RizatriptanRizatriptan Benzoate209$2,845
Lidocaine22$2,618
Pregabalin96$2,563
Celecoxib14$2,438
Duloxetine Hcl48$2,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$8,065$105,22286 claims
PfizerNurtec Odt$10,639$69,06253 claims
Lilly USA, LLCOlanzapine$76$14113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 137 pain medicine providers in Massachusetts.

Other pain medicine in East Sandwich

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →